title: Emergency department visits after intravitreal bevacizumab and ranibizumab injections in diabetic patients.
authors.affiliation: Queen's University, Kingston, Ont.
authors.forename: Davin
authors.initials: D
authors.lastname: Johnson
authors.affiliation: Queen's University, Kingston, Ont.
authors.forename: Lisa
authors.initials: L
authors.lastname: Jagan
authors.affiliation: Queen's University, Kingston, Ont.
authors.forename: Ayaz
authors.initials: A
authors.lastname: Kurji
authors.affiliation: Queen's University, Kingston, Ont.
authors.forename: Klaudia
authors.initials: K
authors.lastname: Jumaa
authors.affiliation: Queen's University, Kingston, Ont.. Electronic address: drsharma@insidermedicine.com.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Sharma
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D004632:Emergency Medical Services / Q000706:statistics & numerical data*; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D015994:Incidence; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D000069579:Ranibizumab; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab